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The prognosis for children with advanced stage neuroblastoma
remains poor despite the increased intensity of treatment over the
last 20 years. Many studies show that although 50–70% of patients
have a very good response to chemotherapy, the majority subse-
quently relapse. This suggests the presence of minimal residual
disease at cessation of therapy despite normal catecholamine
secretion and no detectable signs of neuroblastoma by any method
currently available. An alternative therapeutic approach is re-
quired to prevent these malignant cells from re-entering the growth
cycle.
The in vitro differentiation of certain malignant cell lines
including neuroblastoma can be induced by a variety of agents of
which the retinoids are best studied (Thiele et al, 1985; Lippman et
al, 1987). In vivo, retinoic acid has been shown to induce remis-
sion in promyelocytic leukaemias (Huang et al, 1988) and in xero-
derma pigmentosum a 63% reduction in skin cancer was observed
when patients received oral isotretinoin (Kraemer et al, 1988).
Since 13-Cis retinoic acid has been used in children with xero-
derma pigmentosum for 2 years with acceptable side-effects this
retinoid at a similar low dose was chosen for this study. The aim 
of the study was to establish whether 13-Cis retinoic acid, used as
continuation therapy after obtaining a good response to conven-
tional chemotherapy, could prolong disease free survival in chil-
dren with advanced neuroblastoma.
PATIENTS
175 patients (Table 1) from 10 countries (England, Scotland,
Wales, Belgium, Spain, South Africa, Norway, Sweden, Denmark,
Netherlands) were recruited into the study from 1989 to 1997.
All were in complete remission or very good partial remission
following chemotherapy and were initially Stage 3 or Stage 4
neuroblastoma. Patients from the UK, Belgium and Scandinavian
countries (143 of the 175 entered) followed ENSG protocols with
chemotherapy comprising Vincristine, Carboplatin/Cisplatin,
Etoposide and Cyclophosphamide. The protocols did not include
radiotherapy, and high dose Melphalan was recommended for
children with Stage 4 disease over the age of one year, and stage 3
disease with MYCN amplification (where available). Spanish
patients received the same drugs during induction therapy, but
high dose therapy comprised BCNU and VM26 in addition to
melphalan. I131 mIBG therapy preceded similar chemotherapy for
patients from the Netherlands, and none of the three South African
patients received high dose chemotherapy. Only patients in first
remission were eligible for this study. In all, 126 patients received
high dose melphalan and a transplant and the median time from
diagnosis to the start of 13-Cis retinoic acid therapy was 341 days
(lower quartile 289 days, upper quartile 406 days).
The trial was a double-blind randomized study and randomiza-
tion was stratified for age (less than or greater than 1 year), treat-
ment centre and complete response (CR) versus very good partial
response (VGPR). INSS staging and response criteria were used
(Brodeur et al, 1988). 13-Cis retinoic acid or identical placebo
capsules were given once daily at a dose of 0.75 mg/kg/day with a
milky drink or fat-containing meal. The patients were reviewed,
initially monthly, to check for disease progression or signs of
retinoic acid toxicity. The medication was prescribed for 4 years or
until relapse.
Participating centres obtained protocol approval from the rele-
vant research ethics committees and the randomization procedure
was carried out by the UKCCSG data centre. Twice yearly
progress reports on all patients were requested.
STATISTICAL METHODS
The primary analysis evaluated treatment efficacy by comparison
of all patients in the groups to which they were randomly allocated
– an intention to treat analysis (Peto et al, 1976). The main
endpoint used to evaluate the treatment efficacy was probability of
event-free survival (EFS). This time was defined as the length of
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*On behalf of the European Neuroblastoma Study Grouptime from randomization to earliest detection of relapse or
progression, or death from any cause. Surviving relapse-free
patients were censored at the date of the last clinical follow-up.
The survival curves were calculated by standard methods (Parmar
and Machin, 1995) and confidence intervals calculated. Univariate
analyses were carried out using the log-rank test to evaluate treat-
ment efficacy.
Multivariate analyses were carried out using a proportional
hazards model to estimate the relative benefit of treatment after
adjustment for stage, age greater or less than one year, and abdom-
inal primary tumour or not in a forward stepwise regression.
RESULTS
At the time of analysis in April 1999 median follow-up was 59
months (range 13 to 109 months). 102 patients had died of whom
one died of a second malignancy and one of cerebral haemorrhage
when thrombocytopenic following autografting. All other deaths
were due to relapsed or progressive neuroblastoma. 5 children
were still alive following relapse (i.e. 107 events). 16 patients (9
on placebo, 7 on RA) had completed 4 years treatment.
EFS of all patients is 39.6% at 3 years from randomization (95%
C.I., 32.6% to 47.1%) and 37.3% at 5 years. Survival (S) for all
patients is 42.8% at 3 years from randomization (95% C.I., 35.5%
to 50.4%) and 39.7% at 5 years.
When treatment groups were compared no clear difference in
EFS emerged, 3 year EFS for patients receiving RA 37% vs. 42%
for patients receiving placebo, log-rank test P value 0.62 (Figure 1).
After adjustment for prognostic factors: age under 1, abdominal
primary and bone marrow metastases, the estimated relative treat-
ment benefit remained similar (Hazard ratio 0.95, P value 0.8). No
apparent advantage emerged in high risk patients: for Stage 4 over
the age of 1 year overall 3 year EFS was 32.2%. For patients
receiving RA it was 29% vs. 36% for patients receiving placebo,
log-rank test P value 0.35 (Figure 2).
Compliance with treatment, assessed by parental reporting, was
a problem since the capsules were large and median age at
randomization was 3.5 years (range 0.4 to 21.2 years). The median
time from high dose therapy to randomization was 67 days (lower
quartile 42.5 days, upper quartile 99 days). There was then a delay
of median 1 month before treatment could commence, of similar
length for both treatment arms. The median time from diagnosis to
randomization was 307 days (lower quartile 255 days, upper quar-
tile 382 days). Six patients relapsed before treatment started,
within 2 months of randomization, casting doubt on remission
status at randomization. Four further patients relapsed within 2
months of randomization but had started treatment. 20 patients
took treatment for less than 2 months from starting the first course,
5 because of early relapse and 15 were unable to take capsules for
a variety of reasons. Omitting all 30 patients (of whom 15 were
taking RA and 15 placebo) in a compliance analysis again showed
no benefit in terms of 3 year EFS, for patients receiving RA it was
46% vs. 43% patients receiving placebo, log-rank test P value 0.91
(Figure 3). Re-defining non-compliance as failure to take capsules
for 2 months unless relapsing did not materially change the result.
Toxicity, assessed clinically, was mild and comprised dry skin,
cheilitis or bone pain, reported in both arms of the trial (Table 2).
Treatment was discontinued because of presumed toxicity in only
5 cases. One child had recurrent skin problems and one bone pain,
both were subsequently found to be on retinoic acid. Two children,
both subsequently found to be on placebo, had eye symptoms and
a further child on placebo stopped medication because of slow
blood count recovery following high dose chemotherapy. Since
most children had their central venous lines removed after
3-Cis-retinoic acid in advanced neuroblastoma 1125
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Figure 1 EFS by treatment for all patients
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Figure 2 EFS by treatment for stage 4 over the age of 1 year patients
Table 2 Reported toxicity
RA Placebo
Dry skin 47 29
Cheilitis 24 9
Bone pain 16 16
Other 13 6
Table 1 Patient characteristics
RA Placebo
Total no 88 87
Under 1 year 5 8
Over 1 year 83 79
CR 59 60
VGPR 29 27
UK centres 60 60
Non-UK centres 28 27
Stage 3 11 17
Stage 4 77 70completion of standard chemotherapy, blood tests to check fas-
ting triglyceride levels and liver enzymes were not compulsory.
However, these were requested if blood was being taken for other
reasons, or if the child had clinical signs of toxicity. They were
normal in 35 and abnormal in 9 children tested.
DISCUSSION
In the mid-1980s the only retinoid available for clinical use was
13-Cis retinoic acid. Based on experience with this agent given in
other diseases, such as Xeroderma pigmentosum, the ENSG chose
a dose designed to cause minimal side-effects since most of these
patients had been through many months of extremely intensive
treatment. They were unlikely to tolerate further discomfort for an
experimental medication when the long-term prognosis was poor.
Whilst this trial has been in progress, further studies have been
published showing 13-Cis retinoic acid to be a potent inducer of
differentiation of neuroblastoma in vivo (Reynolds et al, 1991) and
to induce clinical responses in some patients with assessable
disease (Finklestein et al, 1992). A phase 1 trial was carried out by
the Children’s Cancer Group (Villablanca et al, 1995) in patients
who had recently completely myeloablative therapy supported by
bone marrow transplantation. Using a pulsed high dose schedule,
13-Cis retinoic acid was dose-escalated to a maximally tolerated
dose of 160 mg/m2/day with peak drugs levels of 7 µ M.
This led to a phase III trial in which 13-Cis retinoic acid was
given to similar children at 160 mg/m2/day for two weeks per
month for 6 months (Matthay et al, 1999). This was approximately
8 times the daily dose used in the ENSG study, although in the
latter the medication was used continuously over a 4-year period.
High risk patients were more precisely defined in the CCG study
in terms of biology and histology. The results showed a 3-year
EFS rate (from randomization after myeloablative therapy) of 46%
for patients assigned to receive 13-Cis retinoic acid which was
significantly better than the rate of 29% for those assigned to no
further therapy (P = 0.027). Our 3 year EFS rate for all patients of
39.6% (37% RA vs 42% placebo) may reflect not only sub-
optimal 13-Cis retinoic acid levels, but the inclusion of some
‘better risk’ patients.
If only Stage 4 patients over the age of one year are considered,
however, the CCG found a 3 year EFS of 40% for those assigned
to 13-Cis retinoic acid compared with 25% for those assigned
to no further therapy which was not a significant difference 
(P =0.09). Our ENSG figures are 29% and 36% respectively 
(P =0.35). If only the sub-group of Stage 4 patients who were
in complete remission at the end of initial therapy were included
in the CCG analysis, the improved outcome for those receiving
retinoic acid became significant (P = 0.03). In our ENSG study,
the numbers become too small if those in compete remission are
sub-divided from those in very good partial remission. It may also
be that analysing the 3-year event-free survival is premature, and
we must revisit these data in the future.
There are theoretical reasons for prescribing other synthetic
retinoids. 9 Cis-retinoic acid has been shown to be a more effec-
tive differentiating agent in vitro (Lovat et al, 1997), but small
clinical trials in adult patients suggest unacceptable toxicity,
particularly headaches (Miller et al, 1995). Another derivative,
fenretinide, is currently undergoing phase I studies in Italy and the
United States.
This study commenced at a time when important prognostic
factors such as MYCN gene amplification and chromosome 1p
deletion were not widely available in ENSG countries. Definition
of high risk patients was therefore sub-optimal and stratification
for these factors not possible. Nevertheless these factors should be
in approximate balance by virtue of randomization, and a separate
analysis of accepted high risk patients, those over the age of one
year with Stage 4 disease, was carried out.
This study has shown that 13-Cis retinoic acid can be given
continuously at low dosage for a prolonged period of time to chil-
dren with neuroblastoma, but that it does not affect the event-free
survival. The higher dose intermittent schedule used by the CCG is
currently recommended for children in complete response after
initial therapy.
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